Copyright
©The Author(s) 2018.
World J Gastrointest Oncol. Nov 15, 2018; 10(11): 431-438
Published online Nov 15, 2018. doi: 10.4251/wjgo.v10.i11.431
Published online Nov 15, 2018. doi: 10.4251/wjgo.v10.i11.431
Table 2 Analyses of survival outcomes by primary tumor location
| Subgroup | OS events n (%) | Median OS, mo (95%CI) | Hazard ratio (95%CI) | P-value | PFS events n (%) | Median PFS, mo (95%CI) | Hazard ratio (95%CI) | P-value | ||
| Left-sided | Right-sided | Left-sided | Right-sided | |||||||
| All eligible patients (n = 168) | 138 (82.1) | 16.3 (13.5-19.0) | 9.3 (3.4-15.1) | 0.74 (0.48-1.13) | 0.164 | 151 (89.9) | 5.7 (5.3-6.1) | 4.2 (3.2-5.1) | 0.96 (0.64-1.50) | 0.851 |
| KRAS wild type (n = 55) | 44 (76.4) | 17.6 (12.3-22.9) | 15.4 (6.0-24.7) | 0.85 (0.33-2.19) | 0.74 | 51 (92.7) | 5.1 (4.2-5.9) | 4.0 (2.7-5.3) | 0.76 (0.32-1.81) | 0.529 |
| KRAS mutation (n = 25) | 18 (72) | 10.9 (0-34.6) | 9.0 (2.4-15.5) | 0.77 (0.29-2.02) | 0.6 | 22 (88) | 4.8 (2.9-6.6) | 2.1 (0-5.0) | 0.97 (0.36-2.58) | 0.956 |
| KRAS unknown (n = 88) | 78 (88.6) | 16.1 (14.1-18.1) | 9.3 (6.9-11.7) | 0.69 (0.38-1.24) | 0.218 | 78 (88.6) | 6.2 (5.1-7.3) | 6.0 (3.3-8.7) | 0.75 (0.42-1.33) | 0.324 |
| Bevacizumab (n = 29) | 21 (72.4) | 24.5 (16.6-32.3) | 9.3 (-) | 0.30 (0.06-1.43) | 0.11 | 27 (93.1) | 6.2 (4.9-7.4) | 4.0 (-) | 0.45 (0.10-2.01) | 0.285 |
| Cetuximab (n = 16) | 12 (75) | 16.5 (9.0-23.9) | 8.2 (-) | 0.21 (0.03-1.29) | 0.065 | 15 (93.8) | 3.6 (0.89-6.3) | 4.0 (-) | 0.42 (0.08-2.06) | 0.269 |
- Citation: Zhang HY, Guo JH, Gao S, Chen H, Wang XD, Zhang PJ, Liu P, Cao G, Xu HF, Zhu LZ, Yang RJ, Li J, Zhu X. Effect of primary tumor side on survival outcomes in metastatic colorectal cancer patients after hepatic arterial infusion chemotherapy. World J Gastrointest Oncol 2018; 10(11): 431-438
- URL: https://www.wjgnet.com/1948-5204/full/v10/i11/431.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v10.i11.431